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Abstract
Responding to the aggravating shortage of potent antibiotics, pharmaceutical re-
search is constantly looking for new ideas to combat and contain perilous micro-
organisms. As a result of persistent selective pressure, evolution has bestowed
a powerful arsenal of antimicrobial survival strategies upon plants, bacteria and
fungi.
Screening of natural product libraries is an obvious and promising ﬁrst step in an-
timicrobial research. We followed that approach by investigating the antimicrobial
bioactivity of a set of abietane derivatives. To accommodate for the data that re-
sulted from that screening, we then developed a tool to automate and integrate
the data analysis and presentation into the screening workﬂow. In an attempt to
further streamline the process, we evaluated identiﬁcation techniques for micro-
organisms growing in co-cultures based on machine learning. Including the right
material in the screening is a key element for a successful campaign. In our last
study, we analyzed user-generated online sources to search for potential leads for
new anti-infectious drugs.
The screening resulted in a potential new compound active against Staphylococ-
cus aureus with moderate cytotoxicity. The abietane derivative showed a minimal
inhibitory concentration of 60 μg/ml against S. aureus and 8 μg/ml against multi-
resistant S. aureus. Machine learning is used more and more in natural product
research, and our study suggested that random forest classiﬁers and support vec-
tor machines are eﬃcient tools to identify micro-organisms from polymicrobial
cultures. The proposed models had prediction rates >90% in the determination
of growth for microbes in polymicrobial cultures. The Internet is an immense and
ever-growing resource of information, and we sketched a possible way for how
this data can complement the search of antimicrobial plant preparations. In three
examples, we showed correlations between mentions of plants and medical terms.
Centered on antimicrobial screening, this thesis studies diﬀerent strategies to en-
hance the screening process through the help of bioinformatics. We developed,
tested and used diﬀerent tools and methods to support and facilitate library de-
sign, detection techniques, and data management. These are only small pieces
in the search of new antimicrobial compounds, but they show that there are still
many possible approaches to follow.
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Introduction
Vienna, late 1940’s: Investigating the murder of his childhood friend, writer Holly
Martins gets dragged into a ﬂourishing drug smuggling ring. The contraband in
question: penicillin. Thus begins the plot of the 1949 ﬁlm-noir “The Third Man”.
Set during the post-war era, the movie takes place in a time when this new miracle
drug was so scarce and sought after that it was traﬃcked and traded on the black
market.
Since then, the price of penicillin has plummeted. More antibiotics have en-
tered the market and became so abundant that nowadays, it is hard to imagine that
bacterial infections were once serious diseases, often ending in death or disability.
In recent years, however, the situation started to change again, and the demand
for potent antibiotics is growing stronger. Years of imprudent use and neglected
research for novel compounds have taken their toll and led to the emergence of
resistant strains diﬃcult to treat [1].
While the discovery of penicillin was a rather serendipitous event, which has
inspired many young students to leave their laboratory benches in disarray in the
hope of a similar revelation, antibiotic research nowadays is a serious and multi-
faceted venture. From widespread screening of known chemicals to the discovery
of mechanisms that disarm, attenuate and undermine infectious agents, everything
is undertaken to avert a shortage of potent anti-infectives.
In the meantime, antibiotic resistance is growing, and a serious threat arises
frommultiresistant gram-negative species: In the countries of the European Union,
for example, Klebsiella pneumoniæwith combined resistance against ﬂuoroquinolo-
nes, third-generation cephalosporins and aminoglycosides is observed at a growing
rate [2]. In contrast, only 16 out of the 41 antibiotics currently under development,
show signiﬁcant activity against gram-negative bacteria [3]. The fact that during
the past 50 years, only two new classes of antibiotics (ﬂuoroquinolones and ox-
azolidinones) have entered the market, underscores the gravity of the situation
[4].
This thesis describes certain elements of the discovery process for novel antibi-
otics and outlines the development of tools that facilitate that procedure. Starting
9
10 1 Introduction
from the popular yet crude hit-and-miss approach of natural product screening, it
further illustrates the potential of computer-aided methods like machine learning
and information retrieval for the reﬁnement and enrichment of that data.
The present work is but a puzzle piece in the ﬁght against infectious diseases. It
presents strategies and tools that can be used in the search for novel antibiotics and
highlights the importance of natural products and bioinformatics in drug discovery.
Literature Review
2.1 Natural products as drugs
Historical background
In pharmaceutical sciences, the term “natural products (NP)” describes secondary
metabolites from organisms such as plants, fungi and bacteria [5] – these are
molecules that provide an evolutionary beneﬁt, which goes beyond simply sus-
taining life. The roles of NP are many, but often involve interaction with biological
systems, for example to combat parasites or facilitate reproduction [6]. This makes
NP an interesting subject for biomedical research.
Throughout the history of medicine, NP have always occupied a prominent
spot: For centuries, antique herbals, like Dioscorides’ De materia medica, were
used to collect the knowledge of the time and are testimonies of an age when
plants were the main source of remedies [7]. Many plants and herbs were readily
available and easy to gather and cultivate. As such, they were used in virtually
all civilizations around the globe and strongly inﬂuenced the art of curing and
healing. Certain sources even assert that the word “drug” itself is derived from the
Old Dutch word for “dry”, indicating dried herbs and spices [8].
From plants to synthetic drugs
For most of the time, plants were used as whole parts – for example as leaves,
ﬂowers or roots. It was not until the 18th and 19th century, when extensive studies
on plant extracts led to the isolation and identiﬁcation of pure active compounds.
The discovery of digoxin from foxglove (Digitalis) in 1785, morphine from poppies
(Papaver somniferum L.) in 1806 and salicylic acid fromwillow bark (Salix) in 1897
introduced the concept of dose-controlled and deﬁned therapy and marked the
inception of plant-based rational drug discovery [9, 10]. Technological advances
and the progress of chemistry paved the way for the ﬁrst synthetically produced
medicine, salicylic acid. Digoxin, morphine and acetylsalicylic acid are still on
11
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the market today and are a great example of the impact plants have on modern
medicine in our society.
Thanks to their macroscopic size and the ease of investigating, cultivating and
harvesting, plants have for a long time been the center of attention in drug dis-
covery. It was not until 1928, when penicillin was discovered as a by-product of
mold, that fungi became interesting. During the subsequent years, fungi became a
popular subject of research. They constitute a particularly rich source of bioactive
secondary metabolites, which led to the discovery of many nowadays indispensable
drugs – e.g. cephalosporins, cyclosporine, fusidin and griseofulvin [11].
NP also enjoy wide support from the general public and are regularly praised as
preferable alternatives to “chemical” drugs. The reason behind this, however, is not
always because of scientiﬁc reasons. Natural products often play important roles
as ﬂagship remedies in rousseauesque alternative therapies, inspired by naïve and
even esoterical foundations. While this attitude has introduced a certain skepticism
towards NP in the scientiﬁc community, one must not forget that up to this day, NP
are an important source for new drugs [12].
From a chemical perspective, NP are interesting for several reasons: Organisms
have developed ﬁnely-tuned machineries, which are able to synthesize structures,
whose complexity is unmatched by synthetically produced molecules. Due to their
stereochemistry, many NP are diﬃcult to replicate in a laboratory. Taxol (Fig. 2.1),
for example has in total 11 chiral centers, and its total synthesis includes around
20 steps [13].
O
O
O
O
OH
O
O
O
O
OH
O
O
OH
NH
O
Figure 2.1: Taxol, an example of the complex-
ity of secondary metabolites found in plants.
Bacteria and fungi are still the most
promising source for new antibiotics.
Yet large-scale production of micro-
organism-based compounds is dispro-
portionately more diﬃcult than it is
with their plant-based counterparts.
Since ab initio chemical synthesis is of-
ten unfeasible, they are almost exclu-
sively produced through fermentation.
This process is still relatively simple on
research lab scale; an economically vi-
able scale-up proves to be much more
challenging. Since the puriﬁcation and
isolation processes are relatively diﬃ-
cult to optimize, this usually involves
the generation of a highly optimized strains to produce higher yield [14]. Once
isolated, the compounds can be used as-is, or serve as a scaﬀold for optimized
molecules, which lead to a large number of NP derivatives.
Despite their strong bioactivity, many NP surprisingly are not compliant with
Lipinski’s rule of ﬁve (Ro5) for drug-likeness. In synthetic drugs, this would hint
towards lower bioavailability. The structure of NP is, however, similar to endoge-
nous metabolites and hence can be a substrate to cellular transporters [15]. An-
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other property of NP is their notoriously low bioavailability. Recent attempts to
overcome this issue includes the use of nanoparticles, in which the molecules are
incorporated [16].
Outlook
Most NP-based drugs fall into the antimicrobial category (with the noteable ex-
ception of immunosuppressors and statins) [5]. During the post-war period, and
following the discovery of penicillin, a wide variety of antibiotic substances were
isolated from natural sources. Due to the intensive research in this ﬁeld, most
low-hanging fruits have now been harvested [5], and ﬁnding novel antibiotics has
become more diﬃcult. The rapid emergence of resistant bacterial strains dictates
the exploitation of new resources, so researcher can keep successfully ﬁghting in-
fections.
2.2 Antibiotics
The Golden Age of antibiotics
The history of antibiotics is closely intertwined with the history of natural products.
Bacteria populate virtually every niche on this planet, and other organisms have
adapted to their omnipresence by developing survival strategies to ward oﬀ the
pathogens. The antimicrobial repertoire of plants, fungi and bacteria is immense,
and since the discovery of penicillin in 1928 (which was rewarded with the Nobel
prize in medicine in 1945), humans have taken inspiration from natural sources
for the development of most major classes of antibiotics.
Antibiotics entered clinical use in the 1930’s. A few years later, the Golden
Age of antibiotics began: Between the 1940’s and 1970’s, many new compounds
were discovered, developed and optimized (Table 2.1). Fatal bacterial infections
seemed to become a thing of the past. But after 1970, very few new antibiotics
were introduced, and most of them were only slight modiﬁcations of known struc-
tures. The traditional channels of antibiotic discovery seemed exhausted, and the
development of novel antibiotics was stagnating [17, 18]. Bacteria, on the other
hand, kept ﬁghting back, and the emergence of resistant strains threatened to ren-
der known antibiotics ineﬀective. Researchers needed to look for a new source of
antibiotics if they wanted to maintain their dominance.
Antimicrobial resistance
The year 1995 marked the beginning of the genomic era. The sequencing of the
genome revealed new potential targets for antibiotics, and this new technique
looked like the good news antibiotic research was waiting for. Pharmaceutical com-
panies began to run high-throughput screening (HTS) campaigns to screen against
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newly identiﬁed essential targets. Setting up assays was relatively easy, and com-
panies such as GSK had libraries with 260 000–530 000 compounds readily at their
disposal. Despite the optimistic outlook, hit and lead rate from those assays were
uncommonly low, up to 4-5 times lower than for other therapeutic targets. The rea-
sons behind this distortion can be found in the genomes of bacteria. On one hand,
the gene sequences that encoded essential targets in laboratory strains were often
diﬀerent from the ones in wild-type strains, which were therefore not targeted by
the same compounds. The search for broad-spectrum antibiotics was diﬃcult, as
the genomes of two bacterial species are further apart from each other than they
are from humans. The used whole-cell assays made a subsequent detection of the
mode of action (MoA) necessary, and the results were easily tainted by nuisance
compounds. More than 125 screening campaigns, run by 34 companies on 60 tar-
gets, resulted in no new mechanism, and no new structure was discovered from
the companies’ existing libraries [19, 20].
As a consequence, people lost interest in antibiotic research. Success rates were
low, and antibiotics generate relatively little revenue compared to other therapeutic
areas, so many pharmaceutical companies steered clear from antibiotic research
[21].
Shortly after the ﬁrst antibiotic was introduced, bacteria started to develop
resistance against the new threat, and new resistant strains kept emerging even
though antibiotic development was slowing down. The huge initial success of an-
tibiotics also seemed to be their downfall. The widespread – and often wrong –
prescription and bad patient compliance, together with its inconsiderate use in
livestock breeding, led to the emergence of multi-resistant strains, or strains that
are immune to several classes of antibiotics. Traveling and shipping of agricultural
goods helped to spread the resistant strains quickly around the globe.
Among multi-resistant strains, special attention should be directed to the ES-
KAPE strains, which are responsible for the largest contribution to nosocomial in-
fections. The acronym ESKAPE stands for Enterococcus faecium, Staphylococcus
aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,
Enterobacter spp, and hints to their ability to escape most antibiotic treatments
[18].
Outlook
Modern antibiotic research employs diﬀerent strategies to reduce the emergence of
resistant strains. Drugs with new MoA’s can help to circumvent existing resistance
mechanisms. For that reason, screening companies use libraries that cover a large
chemical space, preferably including samples from innovative novel resources.
Oceans and seas harbor huge biodiversity, spanning from algae, fungi and bac-
teria to marine animals. On account of their secluded habitat, marine organisms
have for a long time been neglected as a source of bioactive compounds. During
the last decades, however, they have become the focus of several studies, which
underscore the potential of marine products as novel antibiotic leads [22, 23].
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Themajority of known antibiotics has been discovered by examining soil micro-
organisms, but only a small fraction of them can be cultivated in laboratory condi-
tions. A new device, called “iChip”, allowed researchers to screen these microbes
and ultimately led to the discovery of teixobactin, a novel compound active against
Gram-positive bacteria. For the screening, around 10 000 previously uncultured
strains were planted on a chip, which was then put back into the soil, where the
bacteria could grow in their natural habitat. Teixobactin inhibits cell wall synthe-
sis by binding to a peptidoglycan pre-cursor, and no resistance has been observed
so far [24, 25].
Ethnobotanics, or the study of folk medicine, can support the search for lead
compounds through scientiﬁc analysis of traditional medicines [26, 7]. Kisameet
clay, for example, was used by certain North American aboriginal tribes for its
therapeutic properties. Its antibiotic activity against a broad spectrum of bacteria,
including the ESKAPE-strains, was conﬁrmed in scientiﬁc studies. The antimicro-
bial eﬀect stems from the many micro-organisms to which the clay is a habitat
[27].
Not only exotic places hide medical treasures: Leaf extracts from the Euro-
pean chestnut (Castanea sativa), used in Italian folk medicine for the treatment
of skin infections, has shown potential in the ﬁght against Staphylococcus aureus.
Many of S. aureus’ virulence factors are controlled through a cell-density quorum
sensing mechanism. Components of the extract are able to quench this mecha-
nism, thus suppressing the virulence factors without putting the microbes under
selective stress [28].
Preventing or attenuating infections does not always involve killing the pathogen.
Several other approaches exist and are being developed, for example the encap-
sulation of bacterial endotoxins with liposomes [29]. A study by Czaplewski et al.
[30] lists further approaches for non-bactericidal infection control:
• Antibodies that bind and deactivate virulence factors or toxins;
• Probiotics, i.e. non-pathogenic bacterial cultures, against Clostridium diﬃcile
infection;
• Phage lysins that destroy the cell wall of Gram-positive bacteria, possibly also
in bioﬁlms;
• Bacteriophages, either wild-type or genetically engineered;
• Stimulation of the immune system and vaccines;
• Antibacterial or antibioﬁlm peptides.
Without the selective pressure exercised through ‘traditional’ antibiotics, non-
bactericidal approaches are less likely to cause resistance.
The low output of the antibiotics pipeline, coupled with the soaring amount of
multidrug-resistant germs, have provoked alarming predictions about an imminent
2.3 High-throughput screening 17
post-antibiotic era [31]. As a consequence, the ﬁeld has attracted attention from
academia and healthcare practitioners. Other recent studies paint a more opti-
mistic picture and reveal new strategies, resources and ﬁrst successes in the devel-
opment of new antibiotic structures [32]. If we can overcome the lack of funding
for new projects, the disinterest of Big Pharma and careless antibiotic stewardship,
hopefully future generations will continue to successfully combat infections.
2.3 High-throughput screening
Miniaturization and automation
The slump in the antibiotics pipeline during the 1990’s prompted pharmaceutical
companies to rethink their R&D process. HTSwas not as much a sudden revelation,
as it was rather the result of continuous improvement. Little has been published
about its origins, as it progressed gradually and many companies were working to-
wards miniaturization and rationalization simultaneously. An example from Pﬁzer
suggests that – once again – antibiotics and natural products were the main driving
force behind this process. The screening procedure used at Pﬁzer at the time used
reaction tubes of 1 ml and permitted to screen between 20 and 50 compounds per
week. The higher throughput was achieved with mainly two modiﬁcations: The
storage of compounds in dimethyl sulfoxide (DMSO) and the transfer of the exper-
iments into (initially 24-well) microtiter plates. This led to further miniaturization
and moving towards smaller volumes [33].
ModernHTS facilities currently screen between 10000 and 100 000 compounds
per day; for higher numbers, the term ultra-HTS (uHTS) is used [34]. While the
massive improvements in miniaturization and automation permitted this rapid ad-
vancement on one hand, it was also fueled by the advances in genomics, which
produced a large number of new targets to be tested. From its humble beginnings,
HTS has evolved and is now a mature discipline and a crucial starting point in
modern drug discovery, both in industry and in academia [34, 35]. But despite the
increasing amount of screened compounds, the number of targets for which leads
were developed only increased by 45-55% [36, 37], a success rate that barely jus-
tiﬁes the ﬁnancial investment.
The optimization of HTS can occur at three points: time, cost, and quality.
During the early years, development mainly focused on the ﬁrst two aspects by
pushing miniaturization and automation to their limits. Nowadays, the throughput
rate is reaching its ceiling, and the relevance and quality of the results are getting
more attention than the bare quantity [34].
The design of the assay and its implementation have a direct impact on the
quality of the results. Early HTS used almost exclusively target-based assays, i.e.
assays that ﬁnd molecules targeting a speciﬁc isolated protein. Thanks to their
simplicity, they are relatively easy to implement in HTS format, but oﬀer only
a limited view on the biological eﬀect of the screened samples. An alternative
methodology are phenotypic assays, which observe the eﬀect a compound has on
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a biological system (such as a cell, tissue, or a whole organism). Phenotypic assays
are more challenging to conceive in a HTS-ready format, as they require more
complex setups, and subsequent target identiﬁcation. An intermediate approach
includes the screening of targets in a more natural environment, such as cell lysate
[35, 38].
The development of reliable detection techniques is a further key element in
assay development. The commonly used ﬂuorescence, for example, is prone to pro-
duce false positives. Through technological advancement, methods such as mass
spectrometry (MS) [35] or label-free microarrays [39] can nowadays be utilized
in HTS environments.
Quality issues
With advances being made in HTS assay design, the measurement of the improved
quality is not trivial. Statistical surveillance is important and necessary to quickly
evaluate screens of tens of thousands of compounds. False positives, or samples
erroneously recognized as hits, can lead to unnecessary expenses for follow-up
experiments on a useless compound. False negatives, on the other hand, eliminate
potential drug candidates. The variables used to describe a screen are mean μ
and standard deviation σ of positive control, sample and negative control. Several
metrics have been developed to estimate an assay’s performance, the most simple
being Signal-to-Noise ratio (S/N) and Signal-to-Background ratio (S/B).
The S/N, deﬁned as S/N = μ1−μ2σ2 , describes the ratio between the diﬀerence of
positive and negative response μ1 and μ2 and the standard deviation of the negative
response (or noise) μ2. Similarly, S/B is deﬁned as S/B = μ1μ2 and describes the ratio
between positive and negative response.
Both coeﬃcients are intuitive to understand and simple to calculate, but S/B
does not take into account variability (or σ), and S/N only accounts for variability
in one group (usually the negative control). In order to measure the dynamic range
of the signal and the variability of both sample and background, the Z-factor was
introduced [40]. The Z-factor Z′ = 1 − 3(σp+σn)|μp−μn| estimates statistical eﬀect size
between groups; where it is used to compare positive and negative controls in
HTS, it is usually referred to as Z’. The Z’ combines the advantages of S/N and S/B
and serves as an indicator for how big the chances are that a measurement is a false
positive or negative for normally distributed data points. With Z ′ = 0.0, positive
and negative response are separated by 6 standard deviations, i.e. 99.87% of the
samples will be attributed correctly. For a higher value Z ′ = 0.5, the separation
band is 12 standard deviations wide and the correct classiﬁcation is 99.99966%.
Extrapolated to a screening campaign with 1 000000 samples, this would result
in 3.4 false positives and 3.4 false negatives. HTS assays with a Z ′ > 0.5 are
considered excellent [40].
The cut-oﬀ values for Z’ are mainly empirical, and its probability meaning is not
evident. The strictly standardized mean diﬀerence (SSMD) has been introduced
to compensate for these shortcomings. The SSMD, β = μ1−μ2√
σ21+σ
2
1
, indicates the
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width of the separation band between positive and negative control. For an assay
with Z ′ = 0.5 (i.e. separation of 2× 6σ), the SSMD would be 6 [41].
Not only the how, but also the what is important when setting up a screening
campaign, and library design has received more and more attention during recent
years. There is no general consensus on library design, but diﬀerent approaches are
pursued. Some steps for improving a library are simple, such as storing the sam-
ples at higher concentrations or selecting only a promising subset for a screening
campaign. It was discovered that often, not the size of the library was responsi-
ble for a successful screening campaign, but the chemical space it covered [15].
Access to open-source or pooled and shared libraries allows for improved subset
selection. The preliminary identiﬁcation and elimination of pan-assay interference
compounds (PAINS) can help to reduce the number of false-positive hits, and in
silico absorption, distribution, metabolism, excretion, toxicity (ADMET) predic-
tions prevent the development of hits with small chances of becoming a lead [42].
Libraries usually contain drug-like molecules that comply with the Ro5. When de-
veloping those compounds into leads, the necessary downstream chemistry usually
results in an increase in molecular weight and size and renders them unﬁt as drug
candidates. The introduction of adapted criteria for “candidate-likeness”, like a
rule of four for leads or rule of three for fragments, could prevent that [36].
Different approaches
Some companies have turned their back on HTS and instead experimented with
fragment-based drug design (FBDD). This approach does not screen entire drug-
like compounds, but fragments of low molecular weight <250-300 Da. Good frag-
ment libraries include interesting pharmacophores or privileged structures. Ac-
tive fragments need to undergo extensive downstream chemistry, and fragment–
target interactions are much weaker and more challenging to measure. Commonly
used detection techniques are biophysical methods like surface plasmon resonance
(SPR) or nuclear magnetic resonance (NMR), which are not sensitive to systemic
interactions. The better hit rate of FBDD makes it in some cases preferred over
HTS [43, 35, 36, 44].
A typical FBDD campaign contains around 10 000 fragments. The limiting fac-
tor for higher throughput is the detection by NMR, which takes too long to screen
entire HTS libraries. HTS by NMR is an attempt to reconcile the two techniques
and combine their strengths. At its core lays a combination of protein NMR and
combinatorial chemistry. Instead of testing all possible combinations of fragments,
it measures how a certain fragment at a given position inﬂuences the binding, and
then the best fragments are combined. With x positions and n fragments, it does
not require nx mixtures, but only x× n [35, 44].
It is no coincidence that the ﬂourishing of HTS and the turning away from NP
chronologically coincide. Due to their chemical complexity, NP were diﬃcult to
implement into early-day HTS libraries and assays [9, 15]. The advances made
through twenty years of practicing HTS has brought the technology to a point
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where NP can play to their strengths. Phenotypic assays are more NP-friendly
than target-based ones. Advances in NMR technology makes the elucidation of
structures easier, and research was done on successful pre-fractionation, or the
cleaning of extracts by ﬁltering out compounds that are susceptible lead to false
results. NP libraries intrinsically cover a wider chemical space than combinatorially
produced libraries.
The construction of NP libraries still remains a challenge with many open ques-
tions. An interesting approach is proposed with the “one strain – many com-
pounds” design, which screens the metabolites from only a limited number of
bacterial strains. The bacteria are cultured in diﬀerent conditions in order to ben-
eﬁt from their entire metabolic potential. This approach might include diﬀerent
growth conditions or the supplementation of chemical inducers which alter the
expression proﬁle of the bacteria [14].
HTS and NP are not per se incompatible. Like any new technology, it ﬁrst needs
to mature in order to show its full potential. NP libraries have already shown
their superiority in terms of screening success [9], and it looks like the large-scale
screening of NP is growing in feasibility and popularity.
2.4 Machine learning in drug discovery
The data ﬂood
The mid-1990’s marked a turning point in biomedical research: The freshly de-
coded genome promised to be a cornucopia of novel pharmaceutical targets and
gave access to a whole new dimension of information. Knowing the code for the
secret of life on earth, so was the general consensus, would fuel scientiﬁc progress
in an unprecedented manner. While it took roughly 10 years to decode the ﬁrst
genome [45], technological advances kept up the pace and soon permitted to in-
crease the speed of the process while simultaneously lowering its cost. Modern
next-generation sequencing (NGS) platforms are now able to sequence millions of
DNA molecules in a short time and at an aﬀordable price [46, 47]. The genetic in-
formation, however, – and with it the monumental breakthroughs scientists were
waiting for – was not easy to obtain: The amount of data produced through “-
omics” research and NGS, coupled with automatized high-throughput workﬂows,
was so extensive that the research bottleneck shifted form the generation of data
towards its processing [48, 49]. In some cases, the expenses for storage, security
and analysis of the data even exceeded the costs of its generation [50].
This shift towards data-driven research presented scientists with a new chal-
lenge. Data mining, modeling and analysis became such a prominent element of
the research pipeline that it gave rise to the new ﬁeld of bioinformatics [51, 52].
Situated at the interface of computer science and biology, bioinformatics comprises
the handling, management and processing of biological and clinical data, with ap-
plications in virtual screening, epidemiology or personalized medicine [47, 52].
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An important and often indispensable tool in bioinformatics is machine learn-
ing (ML), a sub-ﬁeld of computer science. ML is an umbrella term used to describe
algorithms that automatize a decision, classiﬁcation or prediction process by infer-
ring rules and ﬁnding patterns from a given data set, rather than following explicit
instructions [51, 53, 54, 55].
Machine learning algorithms (MLA) are very diverse. They can roughly be
divided into two groups: supervised and non-supervised (and the intermediate
semi-supervised) learning. Unsupervised learning is label-free, and the algorithm
tries to classify the data based on their features. This includes dimension-reduction
methods such as principal component analysis (PCA), t-Distributed Stochastic Neigh-
bor Embedding (t-SNE), certain types of artiﬁcial neural networks (ANN), such as
self-organizing maps (SOM), or clustering methods like k-means. In supervised
learning, every sample is labeled, and the algorithm looks for a way to map the
sample to its label. Examples for supervised methods are certain ANN, support-
vectormachines (SVM), naïve Bayes estimators (NB), and genetic algorithms (GA).
ML is particularly useful when it is used to solve data-intensive problems. Com-
mon applications for ML outside biomedical applications include facial recognition,
credit card fraud detection, speech and text recognition, personalized advertise-
ment or Spam detection. In bio- and medtech, it has proved useful in the ﬁelds of
genomics and genetics research [56], drug screening [57], virtual screening (VS)
[58, 59, 60, 61], and image analysis in the context of high-throughput analysis or
high-content screening [54, 62], to name a few.
Microbiologists and doctors rely on the correct identiﬁcation of bacteria for
both research and the correct treatment of infections. Established identiﬁcation
methods exist, but their usefulness can be compromised through constraints in
money, time, or the accuracy they provide. ML has been used to enhance ex-
isting, and develop new, methods for bacterial identiﬁcation, both at genus and
strain level. A common data source for bacterial identiﬁcation is their fatty acid
methyl ester (FAME) proﬁle. FAME-based bacterial identiﬁcation has been pro-
posed in conjunction with ANN [63, 64, 65], random forest (RF)[65], and support-
vector machines (SVM)[65]. In a similar fashion, the FT-IR spectra served as raw
data for analysis with ANN [66, 67]. Identiﬁcation through Matrix-assisted laser
desorption/ionization-time of ﬂight (MALDI-TOF) is a routine analysis in hospitals,
which is usually done by comparing the measured data directly to a database. This
method can be improved by incorporating SVM or RF [68]. A further possibility is
the investigation of Raman forward scattering data with the help of NB [69] and
SVM [69, 70]. The identiﬁcation rates of the diﬀerent methods vary and are in
general between 80 and 99.2 %.
Data analysis with machine learning
Not every algorithm is adequate for every problem, and selecting an appropriate
technique is the ﬁrst step towards building a useful model. Properties of the origi-
nal data, like the proportion of samples to features, the frequency of outliers or the
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presence of strong noise inﬂuence the choice of algorithm. A good understanding
of both the technique and the data is key for the development of a useful model.
Especially in screening, the problem of class imbalance deserves particular atten-
tion. This phenomenon describes failure of the model due to one class being much
larger than the other, for instance during a screening campaign with a low hit rate.
The evaluation of a model is usually done by measuring its overall prediction, even
when either false positives or false negatives should be penalized stronger [71].
Once the right algorithm is chosen, its application follows three steps 1) pre-
processing; 2) training; 3) application (the training step is skipped with unsuper-
vised methods) [54].
1. Pre-processing is often the most diﬃcult, but at the same time a crucial step.
The raw data has to be formatted and transformed to make important fea-
tures accessible to the MLA. This step also condenses the information and
improves the signal-to-noise ratio. In image analysis, pre-processing might
include the extraction of gradient vectors, while VS for example relies on
proper representation of chemical properties or binding parameters.
2. During the training step, the MLA tries to build a model, by trying to ﬁnd the
best way to map the features to the pre-deﬁned labels. The learning process
can only be as good as the chosen training set. The set has to be large enough
to compensate for inconsistencies and representative for the data for which
the model will be used. Since that data is usually unknown, preparing a
good training set can be diﬃcult. Predictions about unknown samples are
always aﬄicted with an uncertainty. A good, consistent training set is key
to counteract under- or overﬁtting of the model or inconsistency of the data
[55].
3. Once a model is built, conﬁgured and trained, it can be applied to unknown
samples. Unsupervised methods get trained during use and may get more
and more accurate throughout time.
ML can easily be used even in smaller labs and research facilities. Most al-
gorithms are freely available through many language implementations such as
Python [72], Matlab [73] and R [74] and come with extensive documentation.
Even though they are computationally more intensive than simple biostatistics, a
modern desktop computer is capable of performing the calculations in reasonable
time.
The need for new, potent antibiotics is undeniable and remains one of the big
challenges in pharmaceutical research today. Plants, fungi and bacteria have al-
ways been, and continue to be, an incredibly rich source for antimicrobial sub-
stances. While the research on natural products was put on hold with the intro-
duction of HTS, this technology nowadays oﬀers a platform to investigate natural
products more extensively. The large amount of data that results from this com-
bination might pose a challenge. Machine learning is a promising approach to
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tackle this problem and hopefully helps to protect future generations from deadly
infections.
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Aims of the Study
The thesis centers on data generation, analysis and management in bioactivity
screening. It includes the search of novel antimicrobial compounds from natural
products and derivatives, and the development of bioinformatics tools to support
that eﬀort.
In particular, this includes the screening of a library of natural product-derived
compounds for antimicrobial activity and the evaluation of the actives for their
potential as candidates for novel antimicrobials (I). To facilitate the process, we
establish a data management tool around a central database (II).
Relying on state-of-the-art data analysis tools, we aspired to develop a ma-
chine learning-based approach to antimicrobial screening permitting to work with
polymicrobial cultures (III), as well as an information retrieval tool to analyze
medical data from blog posts (IV).
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Methods
The drug discovery process is long and non-linear. In this thesis we highlight diﬀer-
ent steps of the process, focusing on the screening element for new antimicrobials
supported with bioinformatic tools. Study I describes the screening assay using
an NP-based library. In study II, we present a solution for the eﬃcient handling
of the generated data. Study III discusses data mining and analysis techniques
to mine the screening results for concealed information. Finally, in study IV, we
developed and used a tool to analyze user-generated data for potential screening
candidates. Those steps cover diﬀerent aspects of the life cycle of screening data,
starting from either de novo generation (I) or retrieval and re-purposing of publicly
available data (IV) over management (II) to analysis (III).
4.1 Data generation
Study I describes the antimicrobial screening of NP-derived compounds. The com-
pounds were based on abietic acid (AA) and dehydroabietic acid (DAA) scaﬀolds
and modiﬁed and optimized to increase antimicrobial activity. Follow-up studies
concerning cytotoxicity completed the analysis.
4.1.1 Compounds
Abietic acid and derivatives
The bioactivity proﬁle of AA and DAA includes antimicrobial [75, 76, 77, 78, 79],
anti-protozoan [80, 81], and anti-tumor [82, 83, 84] activity. Antimicrobial prop-
erties of a novel set of AA and DAA derivatives were investigated in study I.
In total, a set of 10 compounds was screened against Escherichia coli, S. aureus,
and Candida albicans (see also Table 4.1). The compounds were synthesized by the
division of pharmaceutical chemistry and technology, University of Helsinki, based
on AA and DAA with conjugated amino acids.
The compoundswere aliquoted and stored in stock solutions in DMSO at 10mM
and -80 °C.
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(a) Abietic acid (b) Dehydroabietic acid
Figure 4.1: Abietic acid and dehydroabietic acid, starting compounds for study I. Their deriva-
tives showed antimicrobial properties against gram-positive bacteria. Source: ChEMBL
4.1.2 Microbial strains
The microbial strains were selected to cover the main classes of micro-organisms:
Gram-positive and Gram-negative bacteria as well as fungi. We chose to only in-
clude strains that could be handled in a BSL-2 class laboratory. All bacteria and
fungi were stored as glycerol stocks at -80 °C. Table 4.1 summarizes the strains
used in the experiment.
Table 4.1: List of bacterial and fungal strains used in studies I- III.
Strain ATCC Type Used in Growth media Control antibiotic
E. coli 25922 Gram-negative I, III Müller-Hinton broth (MHB) Gentamicin 8 μg/ml
S. aureus 29213 Gram-positive I MHB Ciproﬂoxacin 1 μg/ml
S. aureus 25923 Gram-positive III MHB Ciproﬂoxacin 1 μg/ml
C. albicans 90028 Fungus I, III Sabouraud dextrose agar (SDA) Amphotericin B 16 μg/ml
4.1.3 Screening assay
The screening assays used in study I were carried out according to the clinical &
laboratory standards institute (CLSI) protocol for broth microdilution assay [85].
The screening was divided into primary and secondary screening.
The primary screening was designed to quickly screen the compound library
and identify hits. All the compounds were tested in triplicate at a concentration
of 50 μM. Inhibition of growth was deﬁned as the ratio of absorbance at 620 nm
(Abs620) of the sample to Abs620 of the negative control and calculated according
to equation (4.2). Samples that caused an inhibition > 75% were considered as a
hit and proceeded to the secondary screening.
In the secondary screening, hits were conﬁrmed in a dose–response relation-
ship study. For most compounds, the screening covered a range from 6.25 to 50 μM
in a two-fold dilution series. Where it seemed necessary and adequate, other con-
centrations were also tested.
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Inhibition(%) =
(
1− Abssample −AbsBG
Absneg −AbsBG
)
× 100
Figure 4.2: Inhibition calculation for bacterial growth. Abs denotes measured absorbance of
sample, background BG and negative control neg.
All screening assays were carried out on 96-well microtiter plates, and bacterial
growth was measured photometrically at a wavelength of 620 nm.
Bacteria were incubated for 24 h at 37 °C, fungi for 48 h at 30 °C. During incu-
bation, the plates were shaken in order to minimize aggregation and the formation
of bioﬁlms.
For the analysis of smaller datasets, we used Microsoft Excel. Larger datasets
were analyzed with Python. The quality of the assay was assured through Z’ and
a minimum growth requirement for the untreated (negative) control.
4.1.4 Web search
In order to conﬁrm the novelty of the results from study I, as well as to ﬁnd similar
compounds with a possibly related MoA, we compared the chemical structure of
the hits with existing databases.
We searched ChEMBL and PubChem for compounds with similar molecular
ﬁngerprints using ChEMBL web services and RDKit.
ChEMBL and PubChem are both databases of bioactive molecules; ChEMBL
is maintained by the European Bioinformatics Institute, and PubChem by the Na-
tional Center for Biotechnology Information of the U.S. National Library ofMedicine.
4.2 Data management
In study II, we describe the development of a simple Python module called screen-
ing_mgmt: A tool to handle routine data management tasks from the screening
assay including analysis, annotation and sharing. The module can serve as an in-
terface between the raw data and an SQL database. It automatically treats the
read-out data, analyzes it and stores it to the database, from where it can be re-
trieved later for follow-up analysis or graphic representation.
The design goals for the module were:
• To use only freely accessible tools;
• To keep the module ﬂexible for any kind of screening data;
• To facilitate the use of the module for any user, also outside our lab.
By fully relying on Python andMySQL, all components are platform-independent
and freely available. Other databases such as sqlite are equally supported.
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The two-layer architecture assures that the module is both user-friendly and
ﬂexible at the same time. The simple high-level graphical user interface (GUI)
gives access to the most common operations such as database querying and data
retrieval and presentation. The low-level layer provides a framework for ﬁle input
and output (I/O) and database communication. Its import and export hooks permit
the integration of user scripts and thus provides high ﬂexibility and customization.
Themodule screening_mgmt is hosted on GitHub1 and documented on readthe-
docs.org2. Unit test coverage is momentarily limited to critical key elements and
lies at 15%.
4.3 Data analysis
In study III, we compared 5 diﬀerent MLA for their ability to determine growth in
polymicrobial suspensions. The goal of this study was the development of a cheap
and simple growth determination procedure that relies on a simple data gathering
step and a more sophisticated analysis step.
4.3.1 Raw data
Micro-organisms were incubated overnight in media described in Table 4.1. After
that, they were transferred into Sabouraud dextrose broth (SDB) for the co-culture
in the plate and incubated for 24 h. The ﬁrst set consisted of a total of 8 diﬀer-
ent plates containing none, one or several microbial strains (E. coli E,S. aureus S,
C. albicans C, ES, EC, SC, ESC, 0). The second set contained the polymicrobial ESC
suspension and a selection of reference antibiotics.
Absorbance spectra were measured from a range of 230-800 nm in 2 nm steps.
The dataset used for the analysis included 4 sets× 8 plates× 60 wells× 286 mea-
surements = 549120 data points. After exclusion of machine-dependent errors,
the ﬁnal dataset contained 514 800 data points (286 features × 1800 samples).
Absorbance data was collected onMultiskan GO (Thermo Fisher Scientiﬁc, Vantaa,
FI).
4.3.2 Nested cross-validation
For the comparison of the algorithms, model selection followed nested cross-validation.
In this procedure, the best hyper-parameters for an algorithm are established through
a 3-fold cross-validation, i.e. the dataset was split into training and validation set
in 3 ways. Based on these predictions, the best model and its hyperparameters can
be determined.
1https://github.com/a-hel/screening_mgmt
2http://screening-mgmt.readthedocs.org/en/latest/
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4.3.3 Machine learning algorithms
For the analysis of the data, we used 5 diﬀerent supervised MLA presented here.
In preliminary studies, the datasets were pre-processed with principal component
analysis (PCA) and t-Distributed Stochastic Neighbor Embedding (t-SNE), a step
that did not improve the overall performance.
4.3.4 Principal component analysis
Background
PCA is a dimension reduction technique that projects a high-dimensional dataset
based on the directions of the highest variances. Dimension reduction describes
processes that project high-dimensional data in a lower-dimensional space (usually
2 or 3), for the scope of making them easier to understand. In a good dimension
reduction technique, the transformed data still contains all or most relevant infor-
mation, while noise variables get eliminated. The ﬁrst principal component is the
vector (or direction), along which the highest variance in the dataset can be found.
The following principal components are orthogonal to each other and indicate the
directions of the second, third etc. largest variance. From each dataset, maximum
n principal components can be extracted, where n is the number of dimensions of
the original dataset.
In order to calculate the principal components, the original dataset X is usually
ﬁrst centered and normalized. The components can then be calculated either using
single-value decomposition (SVD) or eigenvalue decomposition (EVD).
PCA is a simple, rapid and useful technique and as such very popular in many
ﬁelds dealing with high-dimensional data. It preserves the global structure of the
dataset and provides a good overview over characteristic variances within that
data. As a downside, the technique is outlier-sensitive, as one value can skew the
principal components in its direction [86, 87, 88].
Implementation
We used scikit’s PCA function, which calculates the principal components using
SVD.
As a simple transformation, PCA is non-parametric. It can be applied to any
dataset, and the interpretation is up to the researcher.
4.3.5 t-SNE
Background
While PCA provides useful results in many applications, local structure of a dataset
can be lost by focusing only on variances. T-SNE, a dimension reduction technique
based on Stochastic Neighbor Embedding [89] addresses this issue, as well as some
other shortcomings of popular dimension reduction and visualization techniques.
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While in PCA, data points far away from each other will be mapped far away, in t-
SNE, the projection also conserves local structure, in a way that similar data points
will remain in proximity. Nonetheless, the global structure remains visible. The
use of a t-stochastic distribution instead of a Gaussian distribution prevents strong
crowding or the accumulation of clusters in the middle in the map. While the orig-
inally proposed algorithm became slow for datasets exceeding 10 000 datapoints,
modern implementations successfully removed that cap [90, 91].
T-SNE can be used to visualize any kind of high-dimensional data, with exam-
ples including Single Nucleotide Polymorphisms [92] or breast cancer screening
data [93].
Implementation
A t-SNE implementation for Python is available from scikit-learn.
In order to accelerate the calculation, it is recommended to preprocess and
reduce datasets with more than 50 dimensions with another dimension reduction
technique ﬁrst, and in our case we used PCA. The perplexity, or the number of
nearest neighbors used by the algorithm, was – following the recommendations in
the user guide – set to 50.
4.3.6 Artiﬁcial neural networks
Background
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Figure 4.3: Schematic of an ANN with one hid-
den layer.
The process of learning is inherently
linked to our brain, and it is not surpris-
ing that artiﬁcial intelligence and ma-
chine learning have tried to imitate the
human learning process. From the sim-
ple abstraction proposed by Rosenblatt
in 1958 to the ambitious Blue Brain
Project [94], the digital representation
of the brain has always fascinated sci-
entists. Nowadays, artiﬁcial neural net-
work (ANN) have evolved to a stage
where they help in guiding self-driving
cars [95] and play (and win) complex
games like chess and Go [96].
In its simplest form, an ANN has at least three layers, each layer consisting
of a number of neurons or nodes: The input layer, where nnodes = nfeatures, one
or more hidden layers, and an output layer with nnodes = nclasses. The layers
are connected with edges (the axons). Upon initialization, all edges are assigned a
randomweight, which is adjusted and optimized during each training cycle. When
the network is given a certain input, the node values at the input layers are then
multiplied with the connected edge weights, and the values are propagated to the
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next layer. At the nodes of the next layers, the signals pass an activation function
(usually the sigmoid function is used). The signal thus traverses all layers until it
reaches the output layer [97].
There are diﬀerent possibilities to train an ANN [98], the most commonly used
is the backpropagation algorithm [99].
Owing to their ﬂexible architecture, ANN are a very powerful and versatile
tool in machine learning and are capable of ﬁnding non-linear relationships in a
wide variety of scenarios [100]. This means, on the other hand, that they are
not an out-of-the-box solution. To fully beneﬁt from its capabilities, the learning
problem needs to be thoroughly examined, and optimization and ﬁne-tuning of
the hyperparameters has to be done carefully.
Implementation
There is a multitude of available Python implementations for ANN. We used Py-
Brain [101], as it is easy to use, well documented and freely available.
We used a simple network with one hidden layer with 143 nodes and a sigmoid
activation function. The network was trained with a backpropagation algorithm
until convergence. During the optimization, we tested it with 1 000 and 10 000
training cycles.
4.3.7 Naïve Bayes classiﬁer
Background
A naïve Bayes (NB) classiﬁer is a probabilistic classiﬁer, which calculates the proba-
bility of a sample belonging to a certain class following Bayes’ theorem. Developed
by Thomas Bayes in the 10th century, the theorem – shown in (4.4) – describes the
posterior probability of an event in function of a prior state.
In a NB, all features are assumed to be independent from each other. While
this assumption is hardly true for most real-live examples and had coined the clas-
siﬁer’s “naïve” attribute, it makes the model scalable for large datasets without
compromises in speed and accuracy [102].
The assumptions that lay the foundation for a NB classiﬁer are simple and,
more often than not, inaccurate if not to say wrong. It is hence surprising that the
classiﬁer works well in many real-life applications like text classiﬁcation or Spam
ﬁltering [103, 104]. This phenomenon has been subject to research, and it was
postulated that NB works best if the features are either completely independent or
completely dependent, while mixed cases lead to worse results [105].
NB is useful in medical diagnosis to evaluate the interplay of diﬀerent risk
factors like in cancer detection [106] or childhood obesity [107], but has also been
applied to other problems such as predicting protein-protein interaction [108] or
drug toxicity [48].
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P (A|B) = P (B|A)P (A)
P (B)
Figure 4.4: Bayes’ theorem. P (A) and P (B) describe the probability of the events A and B,
and P (A|B) the probability of A given B.
Implementation
There is not just one single NB, but it is rather a term for several classiﬁers based
on the same theorem. In our case, we settled for a Gaussian NB, which assumes
that all features are normally distributed, as it is safe to say for large datasets.
The model needs to know the class priors, i.e. the probability of each class. If
this is not the same in the training set as in the real application, this value must be
changed (and estimated) accordingly.
4.3.8 Support-vector machines
Background
Like a line can divide an area or an area can split a cube, any n-dimensional object
can be split by an object (or hyperplane) of (n−1) dimensions. SVM are algorithms
that attempt to ﬁnd such a hyperplane which separates a high-dimensional dataset
in a way that all samples of one class lie on one side of the hyperplane, and all
others on the other side, ideally with a maximal margin between the two sets.
If no optimal hyperplane can be found, the soft-margin implementation of the
algorithm ﬁnds the best possible solution.
In order to ﬁnd the best separating hyperplane, only the datapoints closest to
it (the so-called support vectors) need to be considered for the calculation. As a
result, SVM are relatively light-weight and hence suitable for big data sets. Since
all other datapoints are ignored, the method is also resilient against outliers [109,
110].
Conﬁguring an SVM is not as intricate as, for example, an ANN, but it still holds
some pitfalls for inexperienced researchers. Available step-by-step guidelines can
help the construction of a successful model [111]. While this cookbook approach
does not necessarily lead to the best possible solution, it is a helpful starting point
for researchers less experienced with SVM.
Implementation
There are two popular kernels to use with SVM: Linear and gaussian (or radial
basis function, RBF). A kernel is a function that determines how similarity between
two vectors is measured. Linear kernels are most useful if the number of features
n exceeds the number of training vectors k. In the opposite case, where n  k, a
Gaussian kernel usually gives better results. As in our case, n = 286 and k = 1800,
a Gaussian kernel is preferable [109]. We also considered a polynomial kernel in
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the optimization (of degrees 3, 5, and 7) and penalty parameter C at 1, 10, 100
and 1 000.
4.3.9 Decision trees and random forests
Background
x01 > 0.5
x20 > 1.2
x13 > 0.7
. . . x20 > 1.4
y = E.coli
. . .
. . .
Figure 4.5: Schematic of a decision tree. The
input advances from node to node until it ends
at a prediction.
RF owe their somewhat cryptic name
to the fact that they are, in principle,
a combination of several random de-
cision trees. The algorithm was ﬁrst
described by Breiman [112], when he
tried to solve the random tree’s over-
ﬁtting problem by introducing the con-
cept of bagging.
A decision tree is a hierarchical sys-
tem of nodes and edges. At each level,
the sample is evaluated according to
this node’s criteria until it has reached
the bottom of the tree. The lowest
nodes correspond to the label. If the
tree is large enough to involvemost fea-
tures in the decision process, the tree
tends to overﬁt. In order to counteract
this behavior, RF considers at each node only a random subset of the features for
the splitting, a behavior that is called feature bagging. Each subset is forwarded
to an individual tree with a deﬁned maximum depth. The ﬁnal prediction of the
forest is based on the highest occurrence of predictions of the individual trees.
Two methods are predominantly used when deciding how to split a dataset:
Information gain (also called entropy), where the splitting criteria is based on
which split best classiﬁes the samples, or Gini impurity.
RF are to a certain level resiliant against noise, robust, and, if enough strong
features are present, of formidable accuracy [112, 113].
Implementation
RF is a very popular classiﬁer and many implementations exist. We again used
scikit-learn.
The main parameter of a RF is the number of trees it contains. We used forests
with 10, 25 and 50 trees, split based on entropy or Gini criterion, with maximum
number of features set to auto or log2 and a maximum depth of 50, 100 or None.
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i=nFeat∑
i=1
|li − xi|
Figure 4.6: Evaluation function used for the genetic algorithm. Here, l denotes the label (1 or
0), and x the prediction generated by the individual.
4.3.10 Genetic Algorithm
Background
Nature has always been a source of inspiration for many researchers, engineers
and designers, the aforementioned ANN being just one example. Concepts found
in nature have passed the test of time, and have matured and been optimized
throughout the evolutionary process.
The genetic algorithm (GA), which was proposed by Holland [114], aims to
imitate this evolutionary optimization strategy for everyday problems. The termi-
nology borrows heavily from natural selection: The algorithm starts with a popu-
lation of individuals (set of functions), whose ﬁtness (performance) is evaluated
before they evolve (are modiﬁed) to the next generation (training cycle).
With this method, a classiﬁcation function is continuously built and optimized.
The researcher deﬁnes a pool of node functions and a population size. For each
individual in the population, a node function is then randomly mapped to the
input variables. The results of these individuals are analyzed using an evaluation
function to calculate their ‘ﬁtness’. Individuals with a better ﬁtness have a higher
probability to advance to the next generation, where a new node function is added.
Consistent with the biological evolution, the algorithm also has provisions for cross-
over and random mutations [115, 116]. The algorithm is described in more detail
by Whitley [117].
GA provide a stochastic approach to problem solving. This means, it does not
necessarily produce an optimal solution, but rather the best one it found with the
given parameters. GA are good for problems with many local minima [115], such
as docking studies [118] or protein and peptide structure prediction [119, 120].
Implementation
For the GA, we used the module pyevolve [121], which provided all necessary fea-
tures.
Node functions contained basic arithmetic operations, namely (+), (−), (×),
(÷), and (x2 ). The initial population size was 100 or 500, and they evolved for
100, 300 or 500 generations. Maximum depth was set at 5 or 7, i.e. an individual
is a concatenation of maximum 5 resp. 7 node functions.
The ﬁtness function is shown in (4.6).
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4.4 Data retrieval
In study IV we describe the development of a tool that analyzes blog posts as
an instance of modern ethnopharmacological knowledge. The tool scans posts for
medically relevant terms and analyzes their occurrences and correlations, with the
goal to ﬁnd correlations between mentions of plants or plant material and diseases
or symptoms. The workﬂow is divided into three submodules:
The ﬁrst submodule, the Scraper, is a wrapper for the application programming
interface (API) of blog platforms. It crawls the web and ﬁnds blog posts indexed
with user-deﬁned tags. The basic functionality allows to search WordPress entries,
but other sources can be added if needed.
The second submodule, the Indexer, performs a look-up of the words in the
posts in the current medical subject headings (MeSH) terminology. The search is
implemented as a character-based search tree, where each letter of the MeSH term
is a node of its preceding letter. The words are then compared character-wise, and
as soon as a character is not found, the search is aborted. Otherwise, the preferred
term and its MeSH tree number is returned (Figure 4.7).
In the last submodule, the Grapher, co-occurrences of the MeSH terms are
counted and represented in a network graph. During this step, terms and cate-
gories can be ﬁltered, excluded or highlighted in order to easily see the desired
result.
The tool is written in Python and available on GitHub3; extensive documenta-
tion can be found on readthedocs4. MeSH terms have to be downloaded separately
from the NLM Website5.
3https://github.com/a-hel/medcrawler
4medcrawler.readthedocs.org
5https://www.nlm.nih.gov/mesh/download_mesh.html
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Figure 4.7: Principle of the search tree. Given the MeSH terms grape, grapefruit and growth,
the algorithm advances character-wise. If the last character falls on a node with a tree number,
that number is returned. In any other case, the search is aborted.
Results and Discussion
5.1 Antimicrobial activity of abietic acid derivatives
In study I, we investigated the use of NP as a scaﬀold for novel antimicrobial
lead compounds, starting from a small set of AA derivatives called compounds
1-8. These compounds were then screened against three micro-organisms E. coli,
S. aureus and C. albicans. In the ﬁrst round of screening, compound 8 showed the
strongest eﬀect on microbial growth, inhibiting growth of S. aureus by 76% and
C. albicans by 39%. A second set of analogues was synthesized with the aim to
improve the stability of compound 8, resulting in compounds 9 and 10.
Theminimum inhibitory concentration (MIC90) of compound 10 agains S. aureus
was 60μg/ml and hence comparable to 8, yet the MIC90 of 9 was >125 μg/ml,
indicating a less potent antibiotic eﬀect.
Cytotoxicity, which was assessed by means of lactate dehydrogenase (LDH)
leakage in non-cancerous balb/c 3T3 cells, placed the compounds in the inter-
mediate spectra of reported cytotoxicities of AA derivatives [81]. While this is
not a knock-out criterion, cytotoxicity against mammalian cells can be a serious
unwanted eﬀect which has to be monitored closely during further development.
Cytotoxicity is expressed as EC50 and was measured to be 36 μg/ml for compound
8; compound 9, 48 μg/ml for compound 9 and 45 μg/ml for compound 10.
For compounds 1-10 we then performed a similarity search to ﬁnd related
chemical structures. A survey of available web databases – namely ChEMBL, Pub-
Chem and ChemSpider – did not reveal any reports of the investigated compounds.
Furthermore, a similarity search on ChEMBL yielded no results on antimicrobial ef-
fects of similar compounds. This search compared, however, only the entire struc-
tures and not the potential pharmacophores.
The growth inhibition of 76%, whichwas found for compound 8 against S. aureus,
is not strong enough to qualify the compound itself as a drug candidate, especially
since this value was achieved with the test concentration of 50 μM. Nonetheless,
it is high enough to justify a deeper investigation. While the pharmacological ac-
tion is the most important aspect for a successful drug candidate, it is judicious to
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evaluate key properties, such as cytotoxicity, in parallel, as they might become a
disqualifying factor later in the drug development process.
By evaluating the properties of similar chemical structures, this study also
provides data about the structure-activity relationship (SAR) of AA-derived com-
pounds. This can be used to further optimize the compounds and increase bioac-
tivity and stability, while reducing cytotoxicity.
Antimicrobial activity of AA has been studied for over 20 years [122], and
its antimicrobial eﬀect, as well as that from its derivatives, has been investigated
extensively. Nonetheless, and as it is customary in scientiﬁc publications, most
studies conclude that “further studies are necessary” [78, 79]. Being one of these
further studies, study I complements the knowledge about antimicrobial activity
of AA derivatives. Even though the number of compounds is small for a screening
assay, the results are, thanks to the use of promising startingmaterial, encouraging.
The systematic modiﬁcation with diﬀerent amino acid side chains can furthermore
help future SAR studies and lead the way for further optimization of the AA- and
DAA-derived compounds.
5.2 Development of a data management solution
Automation and miniaturization have helped to generate scientiﬁc data faster, and
the development of powerful microchips permits to analyze that data. Scientiﬁc
research is a highly international discipline and data can be distributed and shared
around the globe. Data transfer requires, however, that the data is well structured,
annotated and understandable. Funding bodies more and more request a data
management plan as part of the grant application, and courses about the data
lifecycle are gaining popularity in the researcher’s curriculum.
The core principle of a screening assay is to quickly measure a certain parame-
ter for a large group of samples. This approach inevitably leads to the generation of
large amounts of data, which need to be administered and maintained. Data man-
agement can be divided into three parts: Infrastructure, data representation and
data analysis [123]. While biocuration – or the art of extracting, storing and main-
taining of biological data – is a veritable interdisciplinary ﬁeld of science [124], the
management of our screening data required only a light-weight tool to handle data
representation and analysis.
Management of large datasets can be a challenge, and the ﬁnancial burden for
small research labs can be considerable [125]. The amount of data, the speed of ac-
cess and the heterogeneous nature of data are often identiﬁed as main challenges
in data management. While the former two things can be addressed with appropri-
ate use of existing technology, the latter requires expertise and in-depth knowledge
and prohibits a one-size-ﬁts-all solution [126]. An ideal data management strat-
egy therefore takes into account the structure of the data, but is extendable to ﬁt
future purposes.
Our dataset comprised results from diﬀerent assays, which all served to de-
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scribe a given set of compounds. That means that each compound record is related
to several diﬀerent assay-speciﬁc records, and new assays may be introduced later.
This structure motivated our choice for a relational database. We used MS SQL, as
it was available through the university’s IT services.
Besides the good representation of our data structure, SQL databases have the
advantage to allow parallel access from diﬀerent collaborators, which sets them
apart from e.g. HDF5 (another common ﬁle format for large scientiﬁc datasets)[127].
HDF5 is, on the other hand, better suited to annotate the data, a shortcoming we
solved by introducing a speciﬁc metadata table in our database.
We developed a Python module, which was on the one hand tailor-made for the
storage of our own results, but at the same time ﬂexible enough to be suitable for a
wide range of applications. Furthermore, it runs platform-independently and can
easily be maintained and developed further. The graphical user interface made it
easy to use for those not versed in Python. It was used in the data management of
the results from paper I and similar experiments.
Centralized storage in an SQL database proved to be an asset in future consul-
tations of the data. Through consistent use of the module, the records were well
ordered, indexed and annotated, as well as accessible through SQL-compatible
software (including Excel or MySQL Workbench).
5.3 Use of machine learning in microbial growth determi-
nation
Biological systems are complex and can hardly ever be described with only one
parameter. Hence, many biological measurements are feature-rich, with features
such as chemical descriptors, pixels of a microscopy image or diﬀerent frequen-
cies. Unfortunately, our human brains are not able to process that multitude of
information at once, and data representations that exceed 3 dimensions are often
counter-intuitive. ML is one approach to investigate enigmatic data and turn it
into human-readable (or understandable) information.
Study III compared ﬁveMLA for determination of bacterial growth from polymi-
crobial cultures. We used absorbance data, which is particularly noise-rich yet easy
and fast to obtain. Diﬀerent MLA are useful for diﬀerent classiﬁcation problems; a
fact clearly mirrored in our research. Overall, the prediction rates of the diﬀerent
algorithms spanned from 39% for ANN to 98% for RF and SVM.
RF is a robust multi-purpose algorithm, but despite its popularity, its mecha-
nistics are not very well understood. The good performance on the test set can be
traced to the fact that RF handles noise variables well and have a built-in mech-
anism against overﬁtting. SVM is another outlier-resistant technique, since it ig-
nores datapoints that are not support vectors. The absorbance spectra were partic-
ularly noise-rich due to the interplay of absorption, light scattering, and bacterial
and fungal concentrations.
The trained model was also applied to a test set with reference antibiotics,
42 5 Results and Discussion
where it showed large variations between individual plates. This shows that the
training set needs to reﬂect the test set well in order to achieve good results. Ac-
counting for class imbalance is a further key element to prevent an ill-ﬁtting model.
The prediction values of the diﬀerent algorithms somewhat correspond to how
diﬃcult it is to optimize them. RF, with its built-in protection from overﬁtting,
performs far better than the notoriously intricate ANN. One has to assume that
experts in the ﬁeld are able to reach better results by not only relying on stan-
dard values for the hyperparameters. Nonetheless, our results still indicate that in
the given circumstances, RF is a solid classiﬁer that does not require an in-depth
understanding of the underlying mechanism.
ML is an interesting asset for enhancing low-quality data sources and extracting
important features from noise-rich data. It oﬀers a versatile toolbox for many data-
related problems in biological applications. While new technologies often have the
reputation to be expensive and only aﬀordable for large buyers, the opposite is
true for many software examples. All algorithms and modules used in study III
are open-source and freely available to the public, and the scripts could run on a
40-euro Raspberry Pi. Our study highlighted that at least some algorithms provide
solid predictions even without time-consuming ﬁne-tuning.
Previously, ML has been used as an additional layer in the identiﬁcation of
micro-organisms. It has been used to enhance existing identiﬁcation techniques
based on ﬁngerprinting methods like Raman and FT-IR spectra [128], FAME pro-
ﬁles, or directly genome sequences, Maldi-TOF [129] (Table 5.1). Due to their high
noise level and strong variability, absorbance spectra, as we used in our study, are
not suitable for simple identiﬁcation. RF are therefore an integral and necessary
part of the identiﬁcation process, and not just another data preparation step.
Table 5.1: Example uses of machine learning in microbiological detection techniques
Strain Level of discrimination Data collection Method Success rate Reference
E. faecalis, E. faecius etc Species FT-IR ANN Goodacre et al. [66]
Marine strains Genus (GC/LC) FAME ANN 90% Giacomini et al. [63]
Campylobacter sp Subspecies FT-IR (Cell) ANN (MLP) 99.16% Mouwen et al. [67]
Leuconostoc, Fructobacillus, Lactococcus Species MALDI-TOF SVM 98.40% De Bruyne et al. [68]
Leuconostoc, Fructobacillus, Lactococcus Species MALDI-TOF RF 94.10% De Bruyne et al. [68]
UTI Species Species Raman SVM 92.00% Kloß et al. [130]
E. coli, C. freudii, E. cloacae Genus Forward scattering NB/SVM 80.00% Marcoux et al. [69]
Burkholderia Species Raman SVM 91.30% Stöckel et al., 2015
5.4 The role of user-generated content in drug discovery
In study IV, we developed a tool to retrieve blog entries from the Internet and
analyze them for medically interesting concepts. Dealing with a large amount of
data, speed and responsible memory usage were main design goals.
In benchmark tests, retrieval of 5 000 posts took 1 134 ± 589 s or roughly
20 min. The overhead due to the search tree construction accounted for 32 s for
∼27 000 MeSH terms; cumulative look-up time for the 5 000 posts clocked in at
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∼4 s.
In order to evaluate the tool’s performance, we produced three examples. Since
the data retrieval is fully automated, caution and common sense are necessary
during the analysis of the results. Semantic context, current events and motivation
of the writer have to be taken into account. The inclusion of large datasets is
advised to rule out outliers and social phenomena that can inﬂuence the results.
Example 1: Anti-infective plants In the ﬁrst example, we retrieved 8 450 posts
for the keywords virus, bacteria, infection, ﬂu, inﬂuenza, common cold, and fever.
Most notable connections were found between inﬂuenza and Echinacea, bacillus
and garlic as well as solanum, and viruses and Eucalyptus (Figure 5.1).
Example 2: Sleep and insomnia The second example investigated sleep disor-
ders using the keywords insomnia, sleepless, and sleep disorder. In the 1 122 posts,
we found connections between sleep and lavender, chamomile and valerian.
Example 3: Headache andmigraine Subject of the third examplewere headaches
and migraine. The keywords headache, pain, and migraine yielded 5 730 posts,
which related migraine to caﬀeine, peppermint, lavender, and citrus.
Figure 5.1: Example network plot generated byMedCrawler. The size of the nodes corresponds
to the total number of mentions, and the width of the edges to the co-occurrences of two MeSH
terms.
A literature analysis of the found associations produced records for most of
them. The level of evidence ranged from meta-analyses over original research pa-
pers to sole mentions of traditional uses. This shows that the tool ﬁnds a wide
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variety of information. Some associations are well-known and scientiﬁcally vali-
dated, others are rather speculative and need to be subject to in-depth analysis.
The value of new media – and blogs in particular – for the scientiﬁc community
has been recognized. Blogs have been appraised as a real-time vehicle for scientists
to share their views and ideas, a platform for doctor-patient interaction or various
educational purposes [131, 132, 133]. In all those cases, only contributions from
knowledgeable peers – scientists, doctors, patients – were included, while the bulk
of available data has been ignored or excluded. As one man’s trash is another
man’s treasure, our tool digs through the raw, unvalidated data to extract and
distill interesting concepts and ideas for scientiﬁc analysis.
Conclusions
Drug discovery is a long, complex and dynamic process, spiked with creativity,
hard work and, more often than not, a handful of serendipity. This thesis tries to
shine a light on certain aspects of the antimicrobial discovery process, particularly
the screening of natural products and their derivatives, as well as data analysis.
NP have traditionally played an important role as starting material for novel an-
timicrobial leads, and a review of the literature and our experiences with NP from
AA, elaborated in study I, show that there are still many untapped resources that
harbor antimicrobial compounds. While for a long time technological shortcom-
ings prohibited the widespread use of NP in HTS, advances in assay development
and detection techniques paved new ways to analyze the NP’s bioactivities in large
numbers.
A bottleneck in HTS is the management, curation and analysis of the huge
amount of generated data. While information technology is capable of handling
the data eﬃciently, the importance of data-related strategies, expertise or tools is
often underestimated. In study II, we present a simple data management tool to
show that, even for small-scale research labs, it is feasible and cheap to develop
a tailor-made data solution. In particular, we highlight the integration of many
freely available open-source resources in our assay pipeline.
Following the open source movement, a large part of software, algorithms and
programming tools have been made freely available and are shared and improved
by the community. Their implementation into the data analysis process is hence
an obvious option. In study III, we make the case for the use of machine learning
to retrieve extra information from screening data. The results show that those
techniques are not a magic bullet, but can play a signiﬁcant role in the reﬁnement
of the data if used judiciously, with a negligible impact on the research budget.
NP have been at the origin of many antibiotics, and it is conceivable that plants
have developed certain survival strategies that have not been discovered yet. How-
ever, the crude, large-scale screening of available material has not delivered the
expected success. One popular strategy analyzes traditionally used plants in order
to construct more targeted screening libraries. The tool we present in study IV
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analyzes user-generated online content as a modern vector of traditional knowl-
edge and helps to gain access to a new layer of information concerning use and
potential eﬀect of plant-based remedies.
Whenever treated with antibiotics, micro-organisms responded with the de-
velopment of resistance mechanisms, and in a struggle for survival they will con-
tinue to do so. In reaction, some scientists alarmingly invoked the idea of a post-
antibiotic era where all antibiotics will fall short. But science is not standing still,
and innovative researchers work hard to ﬁnd new solutions. If the subject gets
the attention it needs – from physicians, researchers, foundations and companies
– there is a good chance humans will keep the upper hand in the ﬁght against
infections for the time to come. With the work presented in this thesis, I hope to
have provided a small contribution towards the containment of bacterial diseases.
References
1 ECDC. European centre for disease prevention and control. Last-line antibiotics
are failing: options to address this urgent threat to patients and healthcare
systems. Technical report, ECDC, Stockholm, 2016.
2 ECDC. European centre for disease prevention and control. Antimicrobial re-
sistance surveillance in Europe 2013. Annual report of the European antimi-
crobial resistance surveillance network (EARS-Net). Technical report, ECDC,
Stockholm, 2014.
3 Jim O’Neill. Securing new drugs for future generations: The pipeline of antibi-
otics. Technical report, Review on antimicrobial resistance, 2015.
4 Kim Lewis. Platforms for antibiotic discovery. Nature Reviews Drug Discovery,
12(5):371–387, 2013.
5 William R Strohl. The role of natural products in a modern drug discovery
program. Drug Discovery Today, 5(2):39–41, 2000.
6 Clarissa Dziggel, Holger Schäfer, and Michael Wink. Tools of pathway recon-
struction and production of economically relevant plant secondary metabolites
in recombinant microorganisms. Biotechnology Journal, 12(1):1600145, 2017.
7 P.O. Staub, L Casu, and M Leonti. Back to the roots: A quantitative survey
of herbal drugs in Dioscorides’ De Materia Medica (ex Matthioli, 1568). Phy-
tomedicine, 23(10):1043–1052, 2016.
8 Harper Douglas. Online etymology dictionary. URL
http://www.etymonline.com/index.php?term=drug.
9 Gilbert M Rishton. Natural products as a robust source of new drugs and drug
leads: Past successes and present day issues. The American Journal of Cardiol-
ogy, 101(10):S43–S49, 2008.
10 Atanas G Atanasov, Birgit Waltenberger, Eva-Maria Pferschy-Wenzig, Thomas
Linder, Christoph Wawrosch, Pavel Uhrin, Veronika Temml, Limei Wang, Ste-
fan Schwaiger, Elke H Heiss, Judith M Rollinger, Daniela Schuster, Johannes M
47
48 References
Breuss, Valery Bochkov, Marko D Mihovilovic, Brigitte Kopp, Rudolf Bauer, Ver-
ena M Dirsch, and Hermann Stuppner. Discovery and resupply of pharmacolog-
ically active plant-derived natural products: A review. Biotechnology Advances,
33(8):1582–1614, 2015.
11 Abid Ali Khan, Nafees Bacha, Bashir Ahmad, Ghosia Lutfullah, Umar Farooq,
and Russell John Cox. Fungi as chemical industries and genetic engineering
for the production of biologically active secondary metabolites. Asian Paciﬁc
Journal of Tropical Biomedicine, 4(11):859–870, 2014.
12 David J Newman and Gordon M Cragg. Natural products as sources of new
drugs from 1981 to 2014. Journal of Natural Products, 79(3):629–661, 2016.
13 K C Nicolaou, Z Yang, J J Liu, H Ueno, P G Nantermet, R K Guy, C F Claiborne,
J Renaud, E A Couladouros, K Paulvannan, and E. J. Sorensen. Total synthesis
of taxol. Nature, 367(6464):630–634, 1994.
14 Victor Fedorenko, Olga Genilloud, Liliya Horbal, Giorgia Letizia Marcone,
Flavia Marinelli, Yossi Paitan, and Eliora Z Ron. Antibacterial discovery and
development: From gene to product and back. BioMed Research International,
2015:1–16, 2015.
15 Alan L Harvey, RuAngelie Edrada-Ebel, and Ronald J Quinn. The re-emergence
of natural products for drug discovery in the genomics era. Nature Reviews Drug
Discovery, 14(2):111–129, 2015.
16 Bin Xu, Rebekah Watkins, Ling Wu, Chenming Zhang, and Richey Davis. Nat-
ural product-based nanomedicine: recent advances and issues. International
Journal of Nanomedicine, 10:6055, 2015.
17 Jon Clardy, Michael A. Fischbach, and Cameron R. Currie. The natural history
of antibiotics. Current Biology, 19(11):R437–R441, 2009.
18 Jack N Pendleton, Sean P Gorman, and Brendan F Gilmore. Clinical relevance
of the ESKAPE pathogens. Expert Review of Anti-Infective Therapy, 11(3):297–
308, 2013.
19 Pan F Chan, David J Holmes, and David J Payne. Finding the gems using ge-
nomic discovery: antibacterial drug discovery strategies – the successes and the
challenges. Drug Discovery Today: Therapeutic Strategies, 1(4):519–527, 2004.
20 David J Payne, Michael N Gwynn, David J Holmes, and David L Pompliano.
Drugs for bad bugs: confronting the challenges of antibacterial discovery. Na-
ture Reviews Drug Discovery, 6(1):29–40, 2007.
21 S Ragnar Norrby, Carl Erik Nord, and Roger Finch. Lack of development of
new antimicrobial drugs: a potential serious threat to public health. The Lancet
Infectious Diseases, 5(2):115–119, 2005.
References 49
22 Florie Desriac, Camille Jégou, Eric Balnois, Benjamin Brillet, Patrick Chevalier,
and Yannick Fleury. Antimicrobial peptides frommarine proteobacteria.Marine
Drugs, 11(10):3632–3660, 2013.
23 Alejandro Mayer, Abimael Rodríguez, Orazio Taglialatela-Scafati, and
Nobuhiro Fusetani. Marine pharmacology in 2009–2011: Marine compounds
with antibacterial, antidiabetic, antifungal, anti-inﬂammatory, antiprotozoal,
antituberculosis, and antiviral activities; aﬀecting the immune and nervous
systems, and other miscellaneous mechanisms of . Marine Drugs, 11(7):2510–
2573, 2013.
24 Losee L Ling, Tanja Schneider, Aaron J Peoples, Amy L Spoering, Ina Engels,
Brian P Conlon, Anna Mueller, Till F Schäberle, Dallas E Hughes, Slava Epstein,
Michael Jones, Linos Lazarides, Victoria A Steadman, Douglas R Cohen, Cin-
tia R Felix, K Ashley Fetterman, William P Millett, Anthony G Nitti, Ashley M
Zullo, Chao Chen, and Kim Lewis. A new antibiotic kills pathogens without
detectable resistance. Nature, 517(7535):455–459, 2015.
25 Laura J V Piddock. Teixobactin, the ﬁrst of a new class of antibiotics discovered
by iChip technology? Journal of Antimicrobial Chemotherapy, 70(10):2679–
2680, 2015.
26 Ronghui Gu, YuehuWang, Bo Long, Edward Kennelly, Shibiao Wu, Bo Liu, Ping
Li, and Chunlin Long. Prospecting for bioactive constituents from traditional
medicinal plants through ethnobotanical approaches. Biological & Pharmaceu-
tical Bulletin, 37(6):903–15, 2014.
27 Shekooh Behroozian, Sarah L Svensson, and Julian Davies. Kisameet clay ex-
hibits potent antibacterial activity against the ESKAPE pathogens. mBio, 7(1):
e01842–15, 2016.
28 Cassandra L Quave, James T Lyles, Jeﬀery S Kavanaugh, Kate Nelson, Corey P
Parlet, Heidi A Crosby, Kristopher P Heilmann, and Alexander R Horswill. Cas-
tanea sativa (European Chestnut) Leaf extracts rich in ursene and oleanene
derivatives block Staphylococcus aureus virulence and pathogenesis without de-
tectable resistance. PLOS ONE, 10(8):e0136486, 2015.
29 Brian D Henry, Daniel R Neill, Katrin Anne Becker, Suzanna Gore, Laura Bricio-
Moreno, Regan Ziobro, Michael J Edwards, Kathrin Mühlemann, Jörg Stein-
mann, Burkhard Kleuser, Lukasz Japtok, Miriam Luginbühl, Heidi Wolfmeier,
André Scherag, Erich Gulbins, Aras Kadioglu, Annette Draeger, and Eduard B
Babiychuk. Engineered liposomes sequester bacterial exotoxins and protect
from severe invasive infections in mice. Nature Biotechnology, 33(1):81–88,
2014.
30 Lloyd Czaplewski, Richard Bax, Martha Clokie, Mike Dawson, Heather Fair-
head, Vincent A Fischetti, Simon Foster, Brendan F Gilmore, Robert E W Han-
cock, David Harper, Ian R Henderson, Kai Hilpert, Brian V Jones, Aras Kadioglu,
50 References
David Knowles, Sigríður Ólafsdóttir, David Payne, Steve Projan, Sunil Shau-
nak, Jared Silverman, Christopher M Thomas, Trevor J Trust, Peter Warn, and
John H Rex. Alternatives to antibiotics—a pipeline portfolio review. The Lancet
Infectious Diseases, 16(2):239–251, 2016.
31 WHO. Antimicrobial resistance: global report on surveillance 2014. WHO
Global Report, 2014.
32 R Draenert, U Seybold, E Grützner, and J R Bogner. Novel antibiotics: Are we
still in the pre–post-antibiotic era? Infection, 43(2):145–151, 2015.
33 D A Pereira and J A Williams. Origin and evolution of high throughput screen-
ing. British Journal of Pharmacology, 152(1):53–61, 2007.
34 Lorenz M Mayr and Dejan Bojanic. Novel trends in high-throughput screening.
Current Opinion in Pharmacology, 9(5):580–588, 2009.
35 Shelby K Doyle, Marius S Pop, Helen L Evans, and Angela N Koehler. Advances
in discovering small molecules to probe protein function in a systems context.
Current Opinion in Chemical Biology, 30:28–36, 2016.
36 Serge Mignani, Scot Huber, Helena Tomás, João Rodrigues, and Jean-Pierre
Majoral. Compound high-quality criteria: a new vision to guide the develop-
ment of drugs, current situation. Drug Discovery Today, 21(4):573–584, 2016.
37 Sandra Fox, Shauna Farr-Jones, Lynne Sopchak, Amy Boggs, Helen Wang
Nicely, Richard Khoury, and Michael Biros. High-throughput screening: Up-
date on practices and success. Journal of Biomolecular Screening, 11(7):864–
869, 2006.
38 Joanne Kotz. Phenotypic screening, take two. Science-Business eXchange, 5(15),
2012.
39 Yung-Shin Sun. Use of microarrays as a high-throughput platform for label-free
biosensing. Journal of Laboratory Automation, 20(4):334–353, 2015.
40 J.-H. Zhang. A simple statistical parameter for use in evaluation and validation
of high throughput screening assays. Journal of Biomolecular Screening, 4(2):
67–73, 1999.
41 Xiaohua Douglas Zhang. A pair of new statistical parameters for quality control
in RNA interference high-throughput screening assays. Genomics, 89(4):552–
561, 2007.
42 Mark J Wigglesworth, David C Murray, Carolyn J Blackett, Michael Kossenjans,
and J WillemM Nissink. Increasing the delivery of next generation therapeutics
from high throughput screening libraries. Current Opinion in Chemical Biology,
26:104–110, 2015.
References 51
43 Mary J Harner, Andreas O Frank, and Stephen W Fesik. Fragment-based drug
discovery using NMR spectroscopy. Journal of Biomolecular NMR, 56(2):65–75,
2013.
44 Bainan Wu, Ziming Zhang, Roberta Noberini, Elisa Barile, Marc Giulianotti,
Clemencia Pinilla, Richard A. Houghten, Elena B. Pasquale, and Maurizio Pel-
lecchia. HTS by NMR of combinatorial Libraries: A fragment-based approach
to ligand discovery. Chemistry & Biology, 20(1):19–33, 2013.
45 Naiem T Issa, Stephen W Byers, and Sivanesan Dakshanamurthy. Big data: the
next frontier for innovation in therapeutics and healthcare. Expert Review of
Clinical Pharmacology, 7(3):293–298, 2014.
46 Alejandra Escobar-Zepeda, Arturo Vera-Ponce de León, and Alejandro Sanchez-
Flores. The road to metagenomics: From microbiology to DNA sequencing
Technologies and Bioinformatics. Frontiers in Genetics, 6:348, 2015.
47 Tsai-Tien Tseng, Alyssa Moore, Jonathan Winkjer, and Tsai-Tien Tseng. Bioin-
formatics resources for MicroRNA discovery. Biomarker Insights, 10(Suppl 4):
53, 2016.
48 Yuji Zhang, Qian Zhu, and Hongfang Liu. Next generation informatics for big
data in precision medicine era. BioData Mining, 8(1):34, 2015.
49 Joshua G Schraiber and Joshua M Akey. Methods and models for unravelling
human evolutionary history. Nature Reviews Genetics, 16(12):727–740, 2015.
50 Fabricio F Costa. Big data in biomedicine. Drug Discovery Today, 19(4):433–
440, 2014.
51 Martin Hofmann-Apitius, Gordon Ball, Stephan Gebel, Shweta Bagewadi,
Bernard de Bono, Reinhard Schneider, Matt Page, Alpha Kodamullil, Erfan
Younesi, Christian Ebeling, Jesper Tegnér, and Luc Canard. Bioinformatics min-
ing and modeling methods for the identiﬁcation of disease mechanisms in neu-
rodegenerative disorders. International Journal of Molecular Sciences, 16(12):
29179–29206, 2015.
52 Jake Luo, Min Wu, Deepika Gopukumar, and Yiqing Zhao. Big Data applica-
tion in biomedical research and health care: A literature review. Biomedical
Informatics Insights, 8:1, 2016.
53 Yalin Baştanlar and Mustafa Özuysal. Introduction to machine learning. In
Methods in molecular biology (Clifton, N.J.), volume 1107, pages 105–128,
2014.
54 Arti Singh, Baskar Ganapathysubramanian, Asheesh Kumar Singh, and Soumik
Sarkar. Machine learning for high-throughput stress phenotyping in plants.
Trends in Plant Science, 21(2):110–124, 2016.
52 References
55 Zoubin Ghahramani. Probabilistic machine learning and artiﬁcial intelligence.
Nature, 521(7553):452–459, 2015.
56 Maxwell W Libbrecht and William Staﬀord Noble. Machine learning applica-
tions in genetics and genomics. Nature Reviews Genetics, 16(6):321–332, 2015.
57 Vadim Alexandrov, Dani Brunner, Taleen Hanania, and Emer Leahy. High-
throughput analysis of behavior for drug discovery. European Journal of Phar-
macology, 750:82–89, 2015.
58 Sabina Smusz, Rafał Kurczab, and Andrzej J Bojarski. A multidimensional anal-
ysis of machine learning methods performance in the classiﬁcation of bioac-
tive compounds. Chemometrics and Intelligent Laboratory Systems, 128:89–100,
2013.
59 Kathrin Heikamp and Jürgen Bajorath. Support vector machines for drug dis-
covery. Expert Opinion on Drug Discovery, 9(1):93–104, 2014.
60 Antonio Lavecchia. Machine-learning approaches in drug discovery: methods
and applications. Drug Discovery Today, 20(3):318–331, 2015.
61 Nicola Jones. Computer science: The learning machines. Nature, 505(7482):
146–148, 2014.
62 Oren Z Kraus and Brendan J Frey. Computer vision for high content screening.
Critical Reviews in Biochemistry and Molecular Biology, 51(2):102–109, 2016.
63 M Giacomini, C Ruggiero, L Calegari, and S Bertone. Artiﬁcial neural net-
work based identiﬁcation of environmental bacteria by gas-chromatographic
and electrophoretic data. Journal of Microbiological Methods, 43(1):45–54,
2000.
64 Bram Slabbinck, Bernard De Baets, Peter Dawyndt, and Paul De Vos. Genus-
wide Bacillus species identiﬁcation through proper artiﬁcial neural network ex-
periments on fatty acid proﬁles. Antonie van Leeuwenhoek, 94(2):187–198,
2008.
65 Bram Slabbinck, Bernard De Baets, Peter Dawyndt, and Paul De Vos. Towards
large-scale FAME-based bacterial species identiﬁcation using machine learning
techniques. Systematic and Applied Microbiology, 32(3):163–176, 2009.
66 Royston Goodacre, Eadaoin M Timmins, Paul J Rooney, Jem J Rowland, and
Douglas B Kell. Rapid identiﬁcation of Streptococcus and Enterococcus species
using diﬀuse reﬂectance-absorbance Fourier transform infrared spectroscopy
and artiﬁcial neural networks. FEMS Microbiology Letters, 140(2-3):233–239,
1996.
References 53
67 D.J.M. Mouwen, R Capita, C Alonso-Calleja, J Prieto-Gómez, and M Prieto. Ar-
tiﬁcial neural network based identiﬁcation of Campylobacter species by Fourier
transform infrared spectroscopy. Journal of Microbiological Methods, 67(1):
131–140, 2006.
68 Katrien De Bruyne, Bram Slabbinck, WillemWaegeman, Paul Vauterin, Bernard
De Baets, and Peter Vandamme. Bacterial species identiﬁcation from MALDI-
TOF mass spectra through data analysis and machine learning. Systematic and
Applied Microbiology, 34(1):20–29, 2011.
69 Pierre R Marcoux, Mathieu Dupoy, Antoine Cuer, Joe-Loïc Kodja, Arthur Lefeb-
vre, Florian Licari, Robin Louvet, Anil Narassiguin, and Frédéric Mallard. Op-
tical forward-scattering for identiﬁcation of bacteria within microcolonies. Ap-
plied Microbiology and Biotechnology, 98(5):2243–2254, 2014.
70 Stephan Stöckel, SusannMeisel, Mandy Elschner, Falk Melzer, Petra Rösch, and
Jürgen Popp. Raman spectroscopic detection and identiﬁcation of Burkholderia
mallei and Burkholderia pseudomallei in feedstuﬀ. Analytical and Bioanalytical
Chemistry, 407(3):787–794, 2015.
71 W.-J. Lin and James J Chen. Class-imbalanced classiﬁers for high-dimensional
data. Brieﬁngs in Bioinformatics, 14(1):13–26, 2013.
72 F Pedregosa, G Varoquaux, A Gramfort, V Michel, B Thirion, O Grisel, M Blon-
del, P Prettenhofer, R Weiss, V Dubourg, J Vanderplas, A Passos, D Courna-
peau, M Brucher, M Perrot, and E Duchesnay. Scikit-learn: Machine learning
in Python. Journal of Machine Learning Research, 12:2825–2830, 2011.
73 MathWorks. Statistics and machine learning tool-
box™: User’s guide (R2015a), 2015. URL
http://se.mathworks.com/help/releases/R2015b/pdf_doc/stats/stats.pdf.
74 R Core Team. R: A language and environment for statistical computing. R Foun-
dation for Statistical Computing, Vienna, Austria, 2015.
75 Sandro Donizete Caetano da Silva, Maria Gorete Mendes de Souza,
Miguel Jorge Oliveira Cardoso, Thais da Silva Moraes, Sérgio Ricardo Ambró-
sio, Rodrigo Cássio Sola Veneziani, and Carlos Henrique G Martins. Antibac-
terial activity of Pinus elliottii against anaerobic bacteria present in primary
endodontic infections. Anaerobe, 30:146–152, 2014.
76 Arturo San Feliciano, Marina Gordaliza, Miguel Salinero, and José del Cor-
ral. Abietane Acids: Sources, biological activities, and therapeutic uses. Planta
Medica, 59(06):485–490, 1993.
77 B Gigante, C Santos, A M Silva, M J M Curto, M S J Nascimento, E Pinto, M Pe-
dro, F Cerqueira, M M Pinto, M P Duarte, A Laires, J Rueﬀ, J Gonçalves, M I
54 References
Pegado, and M L Valdeira. Catechols from abietic acid synthesis and evalua-
tion as bioactive compounds. Bioorganic & Medicinal Chemistry, 11(8):1631–8,
2003.
78 Wen Gu and Shifa Wang. Synthesis and antimicrobial activities of novel 1H-
dibenzo[a,c]carbazoles from dehydroabietic acid. European Journal of Medici-
nal Chemistry, 45(10):4692–4696, 2010.
79 Luís Fernando Leandro, Miguel Jorge Oliveira Cardoso, Sandro Donizeti Cae-
tano Silva, Maria Gorete Mendes Souza, Rodrigo Cassio Sola Veneziani, Ser-
gio Ricardo Ambrosio, and Carlos Henrique Gomes Martins. Antibacterial ac-
tivity of Pinus elliottii and its major compound, dehydroabietic acid, against
multidrug-resistant strains. Journal of Medical Microbiology, 63(Pt_12):1649–
1653, 2014.
80 F Olmo, J.J. Guardia, C Marin, I Messouri, M.J. Rosales, K Urbanová,
I Chayboun, R Chahboun, E.J. Alvarez-Manzaneda, and M Sánchez-Moreno.
Prospects of an alternative treatment against Trypanosoma cruzi based on abi-
etic acid derivatives show promising results in Balb/c mouse model. European
Journal of Medicinal Chemistry, 89:683–690, 2015.
81 Maralinganadoddi P Sadashiva, Raghavendra Gowda, Xianzhu Wu, Gajanan S
Inamdar, Omer F Kuzu, Kanchugarakoppal S Rangappa, Gavin P Robertson,
and D Channe Gowda. A non-cytotoxic N-dehydroabietylamine derivative with
potent antimalarial activity. Experimental Parasitology, 155:68–73, 2015.
82 Xiao-Chao Huang, Meng Wang, Heng-Shan Wang, Zhen-Feng Chen, Ye Zhang,
and Ying-Ming Pan. Synthesis and antitumor activities of novel dipeptide
derivatives derived from dehydroabietic acid. Bioorganic & Medicinal Chem-
istry Letters, 24(6):1511–1518, 2014.
83 Motohiko Ukiya, Takashi Kikuchi, Harukuni Tokuda, Keiichi Tabata, Yumiko
Kimura, Takanari Arai, Yoichiro Ezaki, OsamuOseto, Takashi Suzuki, and Toshi-
hiro Akihisa. Antitumor-promoting eﬀects and cytotoxic activities of dammar
resin triterpenoids and their derivatives. Chemistry & Biodiversity, 7(8):1871–
1884, 2010.
84 Motohiko Ukiya, Takuma Kawaguchi, Kenta Ishii, Eri Ogihara, Yosuke Tachi,
Masahiro Kurita, Yoichiro Ezaki, Makoto Fukatsu, Yasunori Kushi, and Toshi-
hiro Akihisa. Cytotoxic activities of amino acid-conjugate derivatives of
abietane-type diterpenoids against human cancer cell lines. Chemistry & Biodi-
versity, 10(7):1260–1268, 2013.
85 MatthewWikler, Clinical, and Laboratory Standards Institute. Methods for dilu-
tion antimicrobial susceptibility tests for bacteria that grow aerobically : approved
standard. Clinical and Laboratory Standards Institute, Wayne Pa., 8th ed. edi-
tion, 2009.
References 55
86 MathWorks. Principal component analysis of raw data - MATLAB pca - Math-
Works Nordic, 2014. URL http://se.mathworks.com/help/stats/pca.html.
87 Jonathon Shlens. A tutorial on principal component analysis. ArXiv, pages
1–13, 2014.
88 Alan L. Andrew. Eigenvalues and singular values of certain random matrices,
volume 30. Society for Industrial and Applied Mathematics, 1990.
89 Geoﬀrey E Hinton and Sam T Roweis. Stochastic neighbor embedding. In
Advances in neural information processing systems, pages 833–840, 2002.
90 Laurens der Maaten and Geoﬀrey Hinton. Visualizing data using t-SNE. Journal
of Machine Learning Research, 9(2579-2605):85, 2008.
91 Laurens van der Maaten. Accelerating t-SNE using tree-based algorithms. Jour-
nal of Machine Learning Research, 15:3221–3245, 2014.
92 Alexander Platzer. Visualization of SNPs with t-SNE. PLoS ONE, 8(2):e56883,
2013.
93 Andrew R Jamieson, Maryellen L Giger, Karen Drukker, Hui Li, Yading Yuan,
and Neha Bhooshan. Exploring nonlinear feature space dimension reduction
and data representation in breast Cadx with Laplacian eigenmaps and t-SNE.
Medical Physics, 37(1):339–51, 2010.
94 EPFL. The blue brain project - In brief. URL
http://bluebrain.epfl.ch/cms/lang/en/pid/56882.
95 NVIDIA. How deep learning will acceler-
ate self-driving cars - NVIDIA blog, 2015. URL
https://blogs.nvidia.com/blog/2015/02/24/deep-learning-drive/.
96 Dave Lee. Artiﬁcial intelligence: Google’s AlphaGo beats Go master Lee Se-dol.
URL http://www.bbc.com/news/technology-35785875.
97 Jack V Tu. Advantages and disadvantages of using artiﬁcial neural networks
versus logistic regression for predicting medical outcomes. Journal of Clinical
Epidemiology, 49(11):1225–1231, 1996.
98 Freek Stulp and Olivier Sigaud. Many regression algorithms, one uniﬁedmodel:
A review. Neural Networks, 69:60–79, 2015.
99 David E Rumelhart, Geoﬀrey E Hinton, and Ronald J Williams. Learning rep-
resentations by back-propagating errors. Nature, 323(6088):533–536, 1986.
100 Jacques Bourquin, Heinz Schmidli, Peter van Hoogevest, and Hans Leuen-
berger. Advantages of artiﬁcial neural networks (ANNs) as alternative mod-
elling technique for data sets showing non-linear relationships using data from
56 References
a galenical study on a solid dosage form. European Journal of Pharmaceutical
Sciences, 7(1):5–16, 1998.
101 Tom Schaul, Justin Bayer, Daan Wierstra, Yi Sun, Martin Felder, Frank Sehnke,
Thomas Rückstieß, and Jürgen Schmidhuber. PyBrain. Journal of Machine
Learning Research, 2010.
102 Jiawei Han, Micheline Kamber, and Jian Pei. Data mining: concepts and tech-
niques. Elsevier, 2011.
103 Dengsheng Zhang and Guojun Lu. Review of shape representation and descrip-
tion techniques. Pattern Recognition, 37(1):1–19, 2004.
104 Vangelis Metsis, I Androutsopoulos, and G Paliouras. Spam ﬁltering with naive
Bayes–which naive Bayes? Ceas, page 9, 2006.
105 Irina Rish. An empirical study of the naive Bayes classiﬁer. In IJCAI 2001
workshop on empirical methods in artiﬁcial intelligence, volume 3, pages 41–46.
IBM New York, 2001.
106 Khalid Raza and Atif N Hasan. A comprehensive evaluation of machine learning
techniques for cancer class prediction based on microarray data. International
Journal of Bioinformatics Research and Applications, 11(5):397–416, 2015.
107 T M Dugan, S Mukhopadhyay, A Carroll, and S Downs. Machine learning tech-
niques for prediction of early childhood obesity. Applied Clinical Informatics, 6
(3):506–520, 2015.
108 Haijiang Geng, Tao Lu, Xiao Lin, Yu Liu, and Fangrong Yan. Prediction of
protein-protein interaction sites based on naive Bayes classiﬁer. Biochemistry
Research International, 2015:1–7, 2015.
109 Corinna Cortes and Vladimir Vapnik. Support-vector networks. Machine Learn-
ing, 20(3):273–297, 1995.
110 NadeemAhmed Syed, Syed Huan, Liu Kah, and Kay Sung. Incremental learning
with support vector machines, 1999.
111 Chih-Jen Lin Chih-Wei Hsu, Chih-Chung Chang. A practical guide to support
vector classiﬁcation. 2010.
112 Leo Breiman. Random forests. Machine Learning, 45(1):5–32, 2001.
113 Gérard Biau. Analysis of a random forests model. J. Mach. Learn. Res., 13(1):
1063–1095, 2012.
114 John H Holland. Adaptation in natural and artiﬁcial systems: an introductory
analysis with applications to biology, control, and artiﬁcial intelligence. U Michi-
gan Press, 1975.
References 57
115 Tilman Brodmeier and Ernö Pretsch. Application of genetic algorithms in
molecular modeling. Journal of Computational Chemistry, 15(6):588–595,
1994.
116 Royston Goodacre. Explanatory analysis of spectroscopic data using machine
learning of simple, interpretable rules. Vibrational Spectroscopy, 32(1):33–45,
2003.
117 Darrell Whitley. A genetic algorithm tutorial. Statistics and Computing, 4(2):
65–85, 1994.
118 Gareth Jones, Peter Willett, Robert C Glen, Andrew R Leach, and Robin Taylor.
Development and validation of a genetic algorithm for ﬂexible docking. Journal
of Molecular Biology, 267(3):727–748, 1997.
119 Mahmood A Rashid, Sumaiya Iqbal, Firas Khatib, Md Tamjidul Hoque, and Ab-
dul Sattar. Guided macro-mutation in a graded energy based genetic algorithm
for protein structure prediction. Computational Biology and Chemistry, 61:162–
177, 2016.
120 Xiao Ru, Ce Song, and Zijing Lin. A genetic algorithm encoded with the struc-
tural information of amino acids and dipeptides for eﬃcient conformational
searches of oligopeptides. Journal of Computational Chemistry, 37(13):1214–
1222, 2016.
121 Christian S Perone. Pyevolve. ACM SIGEVOlution, 4(1):12–20, 2009.
122 T A Söderberg, R Gref, S Holm, T Elmros, and G Hallmans. Antibacterial activ-
ity of rosin and resin acids in vitro. Scandinavian Journal of Plastic and Recon-
structive Surgery and Hand Surgery, 24(3):199–205, 1990.
123 Alain Viari. Big Data en biologie. médecine/sciences, 28(12):1027–1028, 2012.
124 Nima Salimi and Randi Vita. The viocurator: Connecting and enhancing scien-
tiﬁc data. PLoS Computational Biology, 2(10):e125, 2006.
125 Aisyah Mohd Noor, Lars Holmberg, Cheryl Gillett, and Anita Grigoriadis. Big
Data: the challenge for small research groups in the era of cancer genomics.
British Journal of Cancer, 113(10):1405–1412, 2015.
126 Kerstin A Kessel and Stephanie E Combs. Review of developments in electronic,
clinical data collection, and documentation systems over the last decade – Are
we ready for Big Data in routine health care? Frontiers in Oncology, 6(March):
1–6, 2016.
127 Mike Folk, Gerd Heber, Quincey Koziol, Elena Pourmal, and Dana Robinson. An
overview of the HDF5 technology suite and its applications. In Proceedings of
the EDBT/ICDT 2011 workshop on array databases - AD ’11, pages 36–47, New
York, New York, USA, 2011. ACM Press.
58 References
128 Júlio Trevisan, Plamen P. Angelov, Paul L. Carmichael, Andrew D. Scott, and
Francis L. Martin. Extracting biological information with computational analy-
sis of Fourier-transform infrared (FTIR) biospectroscopy datasets: current prac-
tices to future perspectives. The Analyst, 137(14):3202, 2012.
129 Susmita Datta and Lara M. DePadilla. Feature selection and machine learning
with mass spectrometry data for distinguishing cancer and non-cancer samples.
Statistical Methodology, 3(1):79–92, 2006.
130 Sandra Kloß, Bernd Kampe, Svea Sachse, Petra Rösch, Eberhard Straube, Wolf-
gang Pﬁster, Michael Kiehntopf, and Jürgen Popp. Culture independent Ra-
man spectroscopic identiﬁcation of urinary tract infection pathogens: A proof
of principle study. Analytical Chemistry, 85(20):9610–9616, 2013.
131 Christophe Boudry. [« Biology/medicine 2.0 »: an overview]. Medecine sciences
: M/S, 28(6-7):653–8, 2012.
132 Stephen Rutherford. E pluribus unum : the potential of collaborative learning to
enhance microbiology teaching in higher education: Graphical abstract ﬁgure.
FEMS Microbiology Letters, 362(23):fnv191, 2015.
133 Francisco Jose Grajales III, Samuel Sheps, Kendall Ho, Helen Novak-Lauscher,
and Gunther Eysenbach. Social media: A review and tutorial of applications
in medicine and health care. Journal of Medical Internet Research, 16(2):e13,
2014.
Fighting Bugs by Numbers: Bioinformatics Tools 
for Antimicrobial Drug Discovery
ANDREAS HELFENSTEIN
dissertationes scholae doctoralis ad sanitatem investigandam 
universitatis helsinkiensis 31/2017
31/2017
Helsinki 2017                        ISSN 2342-3161                 ISBN 978-951-51-3131-7  
A
N
D
R
E
A
S H
E
L
FE
N
STE
IN
    Fightin
g B
ugs by N
um
bers: B
ioin
form
atics Tools for A
n
tim
icrobial D
rug D
iscovery
Recent Publications in this Series
11/2017 Lotta von Ossowski
Interaction of GluA1 AMPA Receptor with Synapse-Associated Protein 97
12/2017 Emma Andersson
Characterization of Mature T-Cell Leukemias by Next-Generation Sequencing and Drug 
Sensitivity Testing
13/2017 Solja Nyberg
Job Strain as a Risk Factor for Obesity, Physical Inactivity and Type 2 Diabetes – a Multi-cohort 
Study
14/2017 Eero Smeds
Cortical Processes Related to Motor Stability and Proprioception in Human Adults and 
Newborns
15/2017 Paavo Pietarinen
Effects of Genotype and Phenotype in Personalized Drug Therapy
16/2017 Irene Ylivinkka
Netrins in Glioma Biology: Regulators of Tumor Cell Proliferation, Motility and Stemness
17/2017 Elisa Lázaro Ibáñez
Extracellular Vesicles: Prospects in Prostate Cancer Biomarker Discovery and Drug Delivery 
18/2017 Anu Kaskinen
Measurement of Lung Liquid and Outcome after Congenital Cardiac Surgery
19/2017 Taru Hilander
Molecular Consequences of Transfer-RNA Charging Defects
20/2017 Laura Teirilä
Activation of the Inflammatory Response by Fungal Components
21/2017 Laura Sokka
Burnout in the Brain at Work
22/2018 Martti Rechardt
Metabolic and Inflammatory Factors in Upper Extremity Soft-Tissue Disorders
23/2017 Jaana Hautala
Improving the Palatability of Minitablets for Feline Medication
24/2017 Satu Lehti
Extracellular Lipid Particles in Atherosclerosis and Aortic Stenosis
25/2017 Asko Wegelius
Influence of Birth Weight on the Risk and Clinical Presentation of Schizophrenia
26/2017 Siva P.R. Maddirala Venkata
Public Health and Patient Care Aspects in Pharmacy Education and Pharmacists’ Role in 
National Health Care Programs in India
27/2017 Kristyna Spillerova
The Role of the Angiosome Concept in the Treatment of below the knee Critical Limb Ischemia
28/2017 Anna-Riia Holmström
Learning from Medication Errors in Healthcare  — How to Make 
Medication Error Reporting Systems Work?
29/2017 Aaro Haapaniemi
Laryngeal Cancer Recurrence, Prognostic Factors and Management
30/2017 Reeta Talka
Effects of Opioids on Neuronal Nicotinic Acetylcholine Receptors
DIVISION OF PHARMACEUTICAL BIOSCIENCES
FACULTY OF PHARMACY
DOCTORAL PROGRAMME IN DRUG RESEARCH 
UNIVERSITY OF HELSINKI
